SOMAÍ Launches Soma OG Medical Cannabis Flower in Switzerland
The initial launch includes three indoor-grown cultivars:
• Soap Mints
• The Big Apple
• Cake & Chem
Cultivated at NovaSoma, SOMAÍ’s indoor cultivation facility in Portugal, Soma OG brings together carefully selected genetics, controlled indoor cultivation, and pharmaceutical quality systems to deliver differentiated medical cannabis flower for regulated markets.
Introducing Soma OG to Switzerland
Soma OG was developed as SOMAÍ’s in-house flower brand, created to bring carefully selected indoor-grown cultivars to healthcare professionals and patients through reliable, compliant supply chains.
Built on NovaSoma’s cultivation expertise, the brand reflects SOMAÍ’s broader commitment to consistency, care, and value across its medical cannabis portfolio. Each cultivar is selected for its distinct genetic profile and cultivated under controlled conditions designed to preserve its individual characteristics from harvest to harvest.
Expanding Access Through Dascoli Pharma
Soma OG will be available in Switzerland through Dascoli Pharma AG, building on an established partnership that has already introduced SOMAÍ’s cannabinoid-based medicines to the Swiss market.
“Switzerland continues to be an important market for differentiated cannabinoid products,” said Michael Sassano, Founder and Interim CEO of SOMAÍ. “This launch highlights NovaSoma’s cultivation capabilities and our continued commitment to expanding access to high-quality medical cannabis flower through regulated international markets.”
Andrew Petronanos, Founder and CEO of Dascoli Pharma AG, added: “We are pleased to expand our partnership with SOMAÍ through the launch of Soma OG in Switzerland. Soap Mints, The Big Apple, and Cake & Chem further strengthen the range of medical cannabis flower options available to Swiss healthcare professionals and patients.”
The launch reflects SOMAÍ’s continued investment in cultivation, pharmaceutical infrastructure, and international distribution, supporting the expansion of proprietary cannabinoid products across regulated medical markets worldwide.
About SOMAÍ
SOMAÍ is a leading EU-GMP vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract and flower portfolio.
SOMAÍ owns a state-of-the-art manufacturing facility, SOMAÍ Pharmaceuticals, and indoor cultivation NovaSoma in Lisbon, Portugal, and has global sales teams in the largest medical cannabis markets. We are continuing to make acquisitions and global brand partnerships that make us one of the few and the first European-based vertically integrated companies in the EU able to cater to the diverse needs of fast-growing global cannabis markets.
About Dascoli Pharma
Dascoli Pharma AG is a Swiss pharmaceutical company specializing in medical cannabis, providing an integrated platform for pharmaceutical wholesale, distribution, compounding and nationwide patient supply. Through its wholesale operations and own retail compounding pharmacy, Dascoli Pharma serves healthcare professionals and patients across Switzerland. With a nationwide mail-order licence and daily deliveries throughout the country, the company combines pharmaceutical expertise, reliable access and professional education to support the continued development of medical cannabis in Switzerland.
Nataliia Garnina
SOMAÍ Pharmaceuticals LDA
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
